Search research articles
Contact Us
Filters
Showing results (191-200 of 242) with videos related to
Page
of 25
Sort By:
European Journal of Cancer & Clinical Oncology
|
February 1, 1988
Iproplatin and carboplatin induced toxicities: overview of phase II clinical trial conducted by the EORTC Early Clinical Trials Cooperative Group (ECTG)
M van Glabbeke, J Renard, H M Pinedo, et al.
AIDS (London, England)
|
May 1, 1989
Epidemic Kaposi's sarcoma in Italy, a country with intravenous drug abusers as the major group at risk for AIDS: report of 60 cases
E Vaccher, U Tirelli, A Lazzarin, et al.
AIDS (London, England)
|
July 1, 1989
Unusual malignant tumours in 49 patients with HIV infection
S Monfardini, E Vaccher, G Pizzocaro, et al.
Leukemia
|
May 1, 1993
5-Aza-2'-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes
V Zagonel, G Lo Re, G Marotta, et al.
Haematologica
|
November 1, 1987
Comparison of presenting clinical and laboratory findings of patients with persistent generalized lymphadenopathy (PGL) syndrome and malignant lymphoma (ML)
U Tirelli, E Vaccher, D Serraino, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1993
Phase I-II intraperitoneal mitoxantrone in advanced pretreated ovarian cancer
M O Nicoletto, R Padrini, E Ferrazzi, et al.
Cancer Investigation
|
January 1, 1991
Evaluation of two consecutive regimens in advanced gastric cancer
F Figoli, E Galligioni, D Crivellari, et al.
Cancer Detection and Prevention
|
January 1, 1988
Clinical and laboratory findings at presentation in persistent generalized lymphadenopathy vs malignant lymphoma
V Zagonel, U Tirelli, E Vaccher, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 5, 2004
RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group
C J A Punt, M J A de Jonge, S Monfardini, et al.
Breast Cancer Research and Treatment
|
November 4, 2005
Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer
M Venturini, C Bighin, S Monfardini, et al.
Page
of 25
Search research articles
Search
Showing results (191-200 of 242) with videos related to
Sort By:
Page
of 25
European Journal of Cancer & Clinical Oncology
|
February 1, 1988
Iproplatin and carboplatin induced toxicities: overview of phase II clinical trial conducted by the EORTC Early Clinical Trials Cooperative Group (ECTG)
M van Glabbeke, J Renard, H M Pinedo, et al.
AIDS (London, England)
|
May 1, 1989
Epidemic Kaposi's sarcoma in Italy, a country with intravenous drug abusers as the major group at risk for AIDS: report of 60 cases
E Vaccher, U Tirelli, A Lazzarin, et al.
AIDS (London, England)
|
July 1, 1989
Unusual malignant tumours in 49 patients with HIV infection
S Monfardini, E Vaccher, G Pizzocaro, et al.
Leukemia
|
May 1, 1993
5-Aza-2'-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes
V Zagonel, G Lo Re, G Marotta, et al.
Haematologica
|
November 1, 1987
Comparison of presenting clinical and laboratory findings of patients with persistent generalized lymphadenopathy (PGL) syndrome and malignant lymphoma (ML)
U Tirelli, E Vaccher, D Serraino, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1993
Phase I-II intraperitoneal mitoxantrone in advanced pretreated ovarian cancer
M O Nicoletto, R Padrini, E Ferrazzi, et al.
Cancer Investigation
|
January 1, 1991
Evaluation of two consecutive regimens in advanced gastric cancer
F Figoli, E Galligioni, D Crivellari, et al.
Cancer Detection and Prevention
|
January 1, 1988
Clinical and laboratory findings at presentation in persistent generalized lymphadenopathy vs malignant lymphoma
V Zagonel, U Tirelli, E Vaccher, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 5, 2004
RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group
C J A Punt, M J A de Jonge, S Monfardini, et al.
Breast Cancer Research and Treatment
|
November 4, 2005
Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer
M Venturini, C Bighin, S Monfardini, et al.
Page
of 25